BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25655608)

  • 1. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
    El-Galaly TC; Hutchings M
    Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging of malignant lymphoma.
    Vermoolen MA; Kersten MJ; Fijnheer R; van Leeuwen MS; Kwee TC; Nievelstein RA
    Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of PET in lymphoma.
    Jhanwar YS; Straus DJ
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
    Chavdarova LI; Tzonevska AD; Piperkova EN
    Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL; Jones RJ; Wahl RL
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of advanced non-Hodgkin's lymphoma involving the prostate: staging and treatment monitoring using F-18 FDG PET/CT imaging.
    Cimarelli S; Lachenal F; Ricard F; Chassagne-Clément C; Heudel PE; Janody P; Sebban C
    Clin Nucl Med; 2010 Jun; 35(6):425-7. PubMed ID: 20479591
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of PET/CT to evaluate response to therapy in lymphoma.
    Zanoni L; Cerci JJ; Fanti S
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):633-47. PubMed ID: 22231583
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging for Staging and Response Assessment in Lymphoma.
    Johnson SA; Kumar A; Matasar MJ; Schöder H; Rademaker J
    Radiology; 2015 Aug; 276(2):323-38. PubMed ID: 26203705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
    Goldschmidt N; Or O; Klein M; Savitsky B; Paltiel O
    Ann Hematol; 2011 Feb; 90(2):165-71. PubMed ID: 20706721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of functional imaging in the management of lymphoma.
    Cheson BD
    J Clin Oncol; 2011 May; 29(14):1844-54. PubMed ID: 21482982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.